Search PubMed⌕ Search

Biomedical subjects

Judy Bradley

Publications and source records attributed to Judy Bradley.

4 recordsLinked to original sources

Short-burst oxygen therapy in chronic obstructive pulmonary disease.

INTRODUCTION: Despite widespread prescription, the efficacy of short-burst oxygen therapy has not been established. AIM: To systematically review the available evidence for short-burst oxygen therapy in patients with chronic obstructive pulmonary disease (COPD). METHOD: Retrieval of randomized-controlled trials comparing short-burst oxygen (oxygen for breathlessness at rest, before exercise and after exercise) with placebo in patients with COPD. Data were extracted and, where possible, outcome measures were combined using RevMan analyses 4.2. The methodological quality of each trial was assessed using the PEDro scale. RESULTS: Studies differed in the type of exercise test used, the amount of oxygen delivered and in the length of time for pre- or post-dosing. Quality of the included studies as rated by the PEDro scale was good. For many outcome measures, data could not be pooled for meta-analysis. Short-burst oxygen is primarily indicated for the symptomatic relief of breathlessness, and the bulk of evidence from this review suggests that short-burst oxygen therapy does not reduce breathlessness. For secondary outcome measures (exercise capacity, oxygen saturation [SaO(2)], other ventilatory parameters), the results are not consistent. CONCLUSION: The studies in this review suggest that the widespread prescription of short-burst oxygen is not evidence-based. If prescription is to continue, the scientific rationale for short-burst oxygen therapy must be established.

Evidence-Based Medicine↗

Heart-valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2-ErbB3 receptors.

Heart septation and valve malformations constitute the most common anatomical birth defects. These structures arise from the endocardial cushions within the atrioventricular canal (AVC) through dynamic interactions between cushion cells and the extracellular matrix (termed cardiac jelly). Transformation of endothelial cells to mesenchymal cells is essential for the proper development of the AVC and subsequent septation and valve formation. Atrioventricular septal defects can result from incomplete endocardial cushion morphogenesis. We show that hyaluronan-deficient AVC explants from Has2(-/-) embryos, which normally lack mesenchyme formation, are rescued by heregulin treatment, which restores phosphorylation of ErbB2 and ErbB3. These events were blocked using a soluble ErbB3 molecule, as well as with an inhibitor of ErbB2, herstatin. We show further that ErbB3 is activated during hyaluronan treatment of Has2(-/-) explants. These data provide a link between extracellular matrix-hyaluronan and ErbB receptor activation during development of early heart-valve and septal mesenchyme.

Animals↗